中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (12): 1169-1172.doi: 10.35541/cjd.20240252

• 研究报道 • 上一篇    下一篇

1.5%磷酸芦可替尼乳膏治疗非节段型白癜风5例临床观察

黄贺1，2    唐先发1，2    李蔚然1，2    朱才红1，2    李扬1，2    梁波1，2    李敏3    汪洋1，2    张学军1，2，3    张博2，3   

  1. 1安徽医科大学第一附属医院皮肤科，合肥  230022；2博鳌超级医院皮肤医学中心，琼海  571437；3苏州大学附属第四医院皮肤科，苏州  215000
  • 收稿日期:2024-05-13 修回日期:2025-11-18 发布日期:2025-12-04
  • 通讯作者: 张博 E-mail:alvinbo@163.com
  • 基金资助:
    皮肤病学教育部重点实验室（安徽医科大学）开放课题（AYPYS2024-5）

Ruxolitinib phosphate 1.5% cream for the treatment of five cases of nonsegmental vitiligo

Huang He1,2, Tang Xianfa1,2, Li Weiran1,2, Zhu Caihong1,2, Li Yang1,2, Liang Bo1,2, Li Min3, Wang Yang1,2, Zhang Xuejun1,2,3, Zhang Bo2,3   

  1. 1Department of Dermatology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China; 2Dermatology Center, Boao Super Hospital, Qionghai 571437, China; 3Department of Dermatology, the Fourth Affiliated Hospital of Soochow University, Suzhou 215000, China
  • Received:2024-05-13 Revised:2025-11-18 Published:2025-12-04
  • Contact: Zhang Bo E-mail:alvinbo@163.com
  • Supported by:
    The Open Project of Key Laboratory of Dermatology（Anhui Medical University）, Ministry of Education（AYPYS2024-5）

PDF

0

摘要： 【摘要】 目的 观察1.5%磷酸芦可替尼乳膏治疗5例非节段型白癜风的疗效及不良反应。方法 本研究为病例系列研究，收集2023年8月至2024年4月于博鳌超级医院就诊的5例非节段型白癜风患者，予单独外用1.5%磷酸芦可替尼乳膏2次/d治疗，治疗12、24周时采用面部白癜风面积评分指数（F-VASI）和全身白癜风面积评分指数（T-VASI）评估疗效，同时监测治疗过程中的不良反应。结果 5例非节段型白癜风患者年龄28 ~ 43岁，病程4 ~ 30年，皮损累及面部和非面部部位，白癜风累及体表面积2.6% ~ 6.9%。治疗12周时，3例F-VASI改善75%（F-VASI 75），2例达到T-VASI 50；治疗24周时，5例均达到F-VASI 50，其中3例达到F-VASI 90，2例达到T-VASI 50。治疗过程中1例用药部位出现痤疮，2例出现脱皮，2例出现瘙痒，均未影响治疗。结论 1.5%磷酸芦可替尼乳膏可作为非节段型白癜风的治疗选择。

关键词: 白癜风, 治疗, 芦可替尼乳膏, 有效性, 安全性

Abstract: 【Abstract】 Objective To evaluate the efficacy and safety of ruxolitinib phosphate 1.5% cream in the treatment of 5 cases of nonsegmental vitiligo. Methods A case series study was conducted. Five patients with nonsegmental vitiligo were collected from the Boao Super Hospital between August 2023 and April 2024. All the patients were treated with topical ruxolitinib phosphate 1.5% cream alone twice daily. Efficacy was assessed at weeks 12 and 24 using the Facial Vitiligo Area Scoring Index （F-VASI） and the Total Vitiligo Area Scoring Index （T-VASI）. During the treatment, adverse reactions were monitored. Results The 5 patients were aged 28 - 43 years, with the disease duration ranging from 4 to 30 years. Lesions involved both facial and non-facial areas, with the affected body surface area ranging from 2.6% to 6.9%. After 12 weeks of treatment, 3 patients achieved 75% improvement in facial lesions （F-VASI 75）, and 2 achieved T-VASI 50. After 24 weeks of treatment, all patients achieved F-VASI 50, including 3 achieving F-VASI 90 and 2 achieving T-VASI 50. During the treatment, adverse reactions included application-site acne （1 case）, application-site exfoliation （2 cases）, and application-site pruritus （2 cases）; none of these adverse reactions affected the treatment. Conclusion Ruxolitinib phosphate 1.5% cream may serve as a treatment option for nonsegmental vitiligo.

Key words: Vitiligo, Therapy, Ruxolitinib cream, Efficacy, Safety

引用本文

黄贺, 唐先发, 李蔚然, 朱才红, 李扬, 梁波, 李敏 汪洋, 张学军, 张博, . 1.5%磷酸芦可替尼乳膏治疗非节段型白癜风5例临床观察[J]. 中华皮肤科杂志, 2025,58(12):1169-1172. doi:10.35541/cjd.20240252

Huang He, Tang Xianfa, Li Weiran, Zhu Caihong, Li Yang, Liang Bo, Li Min, Wang Yang, Zhang Xuejun, Zhang Bo, . Ruxolitinib phosphate 1.5% cream for the treatment of five cases of nonsegmental vitiligo[J]. Chinese Journal of Dermatology, 2025, 58(12): 1169-1172.doi:10.35541/cjd.20240252